ImmunityBioIBRX
IBRX
About: ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
Employees: 672
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
71% more call options, than puts
Call options by funds: $18.7M | Put options by funds: $10.9M
48% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 42
0.87% more ownership
Funds ownership: 9.0% [Q2] → 9.86% (+0.87%) [Q3]
6% less funds holding
Funds holding: 191 [Q2] → 180 (-11) [Q3]
31% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 35
35% less capital invested
Capital invested by funds: $393M [Q2] → $256M (-$138M) [Q3]
100% less funds holding in top 10
Funds holding in top 10: 2 [Q2] → 0 (-2) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
1,045%
upside
Avg. target
$30
1,045%
upside
High target
$30
1,045%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 25% 1-year accuracy 38 / 150 met price target | 1,045%upside $30 | Buy Maintained | 20 Dec 2024 |
EF Hutton Jason Kolbert 25% 1-year accuracy 38 / 150 met price target | 1,045%upside $30 | Buy Initiated | 23 Oct 2024 |
Financial journalist opinion
Based on 6 articles about IBRX published over the past 30 days
Positive
Seeking Alpha
5 days ago
ImmunityBio: Forging A New Plan After Recent $100 Million Offering
ImmunityBio's recent $100M public offering was necessary to support ANKTIVA's commercialization and pipeline programs, despite the dilution and lower offering price of $3 per share. The company's cash burn rate and financial health remain concerns, but ANKTIVA's impressive performance and future milestones could drive substantial growth and extend the cash runway. IBRX's financial risks persist, and multiple offerings may be needed before profitability, but the potential for explosive revenue growth by 2029 supports a bullish outlook.
Positive
Seeking Alpha
1 week ago
ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success
ImmunityBio's Anktiva shows promise with potential peak revenues of ~$900m annually, but faces significant competition and financial challenges, including a poorly timed $100m fundraising effort. Despite recent setbacks, including a Q3 net loss of $80m and a cash position of $130m, I maintain a "Buy" rating, anticipating positive 2025 catalysts. Anktiva's efficacy in NMIBC and potential in NSCLC + other cancers are potentially compelling, but the company needs substantial funding to complete ongoing and planned clinical studies.
Neutral
GlobeNewsWire
1 week ago
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering
CULVER CITY, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an aggregate of 33,333,334 shares of its common stock at a price to the public of $3.00 per share. ImmunityBio has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares were sold by ImmunityBio. Before deducting the underwriting discount and offering expenses payable by ImmunityBio, ImmunityBio expects to receive gross proceeds of approximately $100.0 million, assuming no exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about December 12, 2024 subject to satisfaction of customary closing conditions.
Neutral
Business Wire
1 week ago
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an aggregate of 33,333,334 shares of its common stock at a price to the public of $3.00 per share. ImmunityBio has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of.
Neutral
Business Wire
1 week ago
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, ImmunityBio expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions.
Neutral
PRNewsWire
4 weeks ago
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
FREMONT, Calif. , Nov. 21, 2024 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated biotechnology company, and nCartes, Inc., a transformational cloud software platform provider, announced a collaboration agreement aimed at automating and streamlining the data fulfillment process for clinical trials.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 184.4% in ImmunityBio (IBRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
PRNewsWire
1 month ago
ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements
SAN FRANCISCO , Nov. 19, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises ImmunityBio, Inc. investors that the firm is investigating potential legal claims relating to the company's unsuccessful efforts in 2023 to secure regulatory approval for its flagship product Anktiva, designed to treat bladder cancer. Current shareholders are encouraged to contact the firm.
Neutral
Business Wire
1 month ago
ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced compelling new data from its ongoing QUILT 3.032 study. As of November 2024, 100 patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (NMIBC CIS) have been treated with ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with BCG, achieving a 71% complete response (CR) rate. In these responders, the range.
Negative
Zacks Investment Research
1 month ago
ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.19 per share a year ago.
Charts implemented using Lightweight Charts™